Kamada Will Supply COVID-19 Treatment to Israel
Israeli biotech Kamada (NASDAQ: KMDA) announced a supply agreement with the Israeli Ministry of Health for its investigational COVID-19 treatment on Monday. The treatment is a hyperimmune immunoglobulin (IgG) product derived from convalescent plasma of volunteers who have recovered from COVID-19. The initial order will be sufficient to treat 500 patients.
In a statement, the company said that this deal "represents the first such contract globally for the supply of a plasma-derived igG product for COVID-19." Kamada's treatment is currently in an ongoing phase 1/2 clinical trial in Israel. Interim results have been positive. According to CEO Amir London, the IgG treatment has "demonstrated a favorable safety profile and showed symptoms improvement in hospitalized, non-ventilated COVID-19 patients with pneumonia ... ."
Image source: Getty Images.
Source Fool.com
